LeonaBio (LONA) Return on Capital Employed (2020 - 2026)
LeonaBio (LONA) posted quarterly Return on Capital Employed of 146.19% for Q1 2026, up 3506.0% year-over-year from 4.05% in Q1 2025, and up 80.57% quarter-over-quarter from 752.56% in Q4 2025.
LeonaBio (LONA) Return on Capital Employed (2020 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Return on Capital Employed for 7 consecutive years, with 146.19% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 3506.0% year-over-year to 146.19%; the TTM figure through Mar 2026 stood at 146.19% (up 3506.0% YoY), while the FY2025 annual figure was 365.73%, down 26104.0% from the prior year.
- Return on Capital Employed rose to 146.19% in Q1 2026 per LONA's latest filing, from 752.56% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.48% in Q1 2022 and bottomed at 752.56% in Q4 2025.
- Historically, Return on Capital Employed has averaged 137.67% across 5 years, with a median of 101.76% in 2024.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 58263 bps — and 2026, when it jumped 3506 bps.
- LeonaBio's Return on Capital Employed stood at 42.5% in 2022, then tumbled by 106 bps to 87.35% in 2023, then tumbled by 95 bps to 169.93% in 2024, then slumped by 343 bps to 752.56% in 2025, then soared by 81 bps to 146.19% in 2026.
- Business Quant data shows LONA's Return on Capital Employed at 146.19% in Q1 2026, 752.56% in Q4 2025, and 130.88% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | LeonaBio | 180.91 Mn | 129.85 Mn | - | -216.40% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -146.19% |
| Dec 31, 2025 | -752.56% |
| Sep 30, 2025 | -130.88% |
| Jun 30, 2025 | -169.68% |
| Mar 31, 2025 | -181.26% |
| Dec 31, 2024 | -169.93% |
| Sep 30, 2024 | -161.06% |
| Jun 30, 2024 | -125.48% |
| Mar 31, 2024 | -101.76% |
| Dec 31, 2023 | -87.35% |
| Sep 30, 2023 | -77.13% |
| Jun 30, 2023 | -59.61% |
| Mar 31, 2023 | -49.00% |
| Dec 31, 2022 | -42.50% |
| Sep 30, 2022 | -32.94% |
| Jun 30, 2022 | -28.54% |
| Mar 31, 2022 | -24.48% |
| Dec 31, 2021 | -19.38% |
| Sep 30, 2021 | -15.78% |
| Jun 30, 2021 | -12.29% |